The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

- Median Overall Survival Not Reached Yet – 67% of Patients Still Alive - ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...

Objective This study aims to calculate the global warming potential, in carbon dioxide (CO 2) equivalent emissions, from all in-scope activities involved in phase 1, 2, 3 and 4 clinical trials ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...